Satellos Bioscience Announces Results of Annual Meeting of Shareholders

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the “Meeting”).

Satellos is pleased to announce that all the nominees listed in the management information circular dated May 14, 2026 (the “Circular”) were elected as directors. Shareholders present at the Meeting or represented by proxy totaled 55.3% of the issued and outstanding common shares of the Company.

The results of the vote are detailed below:

Director	Votes For		% For		Votes Against		% Against
Frank Gleeson	9,473,905		99.94		5,348		0.06
Franklin M. Berger	9,478,576		99.99		677		0.01
Brian Bloom	9,476,755		99.97		2,498		0.03
Stephanie Brown	8,741,404		92.22		737,849		7.78
Selwyn Ho	9,473,538		99.94		5,715		0.06
Iris Loew-Friedrich	7,939,800		83.76		1,539,453		16.24
Geoff Mackay	9,449,959		99.69		29,294		0.31
Adam Mostafa	9,450,311		99.69		28,942		0.31
Mark Nawacki	9,477,041		99.98		2,212		0.02

Schreibe Deinen Kommentar